Jazz Pharmaceuticals plc has promoted Samantha Pearce, Senior Vice President (SVP), Europe and International, to Chief Commercial Officer (CCO) effective August 1, 2024.

Experience

Pearce joined Jazz as SVP, Europe and International, in 2020, and brings more than 30 years of commercial experience in the pharmaceutical industry. Since joining Jazz, she has instilled a commitment to a high-performance culture, growing Jazz’s commercial brands and harnessing the potential of Jazz’s European and International business to provide transformative medicines for patients in more than 50 countries.

From March 2010 to December 2019, Pearce held general management positions across an increasing breadth of global markets with Celgene Corporation, most recently as vice president and general manager of international markets. Prior to that, from August 2002 to March 2010, she served in commercial management positions at AstraZeneca plc, culminating in her role as director of specialist care. Prior to August 2002, she worked for DuPont Pharmaceuticals. She received a B.Sc. from Birmingham University, U.K. and an M.B.A. from Cranfield University, U.K.

In her role as Chief Commercial Officer, Pearson will be responsible for strategy and execution for Jazz’s commercial business across all global markets and will be based in the U.S.

“I am delighted to be stepping into the role of CCO and look forward to leading the combined commercial organization as we continue to scale. I am deeply invested in Jazz’s mission and purpose to help patients and remain focused on our commitment to deliver sustainable growth and enhanced value as an innovative global biopharmaceutical company,” said Pearce. “I have had the privilege of leading Jazz’s Europe and International organization since 2020 and look forward to continuing to partner closely with talented Jazz colleagues to unlock the potential of our business and deliver innovative, life-changing medicines for people with serious diseases.”

This news comes months after Jazz Pharmaceuticals, which agreed to acquire Redx’s KRAS (Kirsten rat sarcoma virus) inhibitor program earlier this year, appointed Philip Johnson as Executive Vice President and Chief Financial Officer.